Cover Image
市場調查報告書

癌檢驗/篩檢市場預測:影像·生物標記·放射線·其他

Cancer Testing/Screening Market - By Cancer Type (Lung, Blood, Bone, Others); By Technique (Imaging, Bio Marker, Radiation, Others); By Product (Molecular & Companion Testing); By Stage; By Gender; By Geography - (2015-2023)

出版商 IndustryARC 商品編碼 622599
出版日期 內容資訊 英文 156 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
癌檢驗/篩檢市場預測:影像·生物標記·放射線·其他 Cancer Testing/Screening Market - By Cancer Type (Lung, Blood, Bone, Others); By Technique (Imaging, Bio Marker, Radiation, Others); By Product (Molecular & Companion Testing); By Stage; By Gender; By Geography - (2015-2023)
出版日期: 2017年11月10日 內容資訊: 英文 156 Pages
簡介

本報告提供全球癌檢驗/篩檢的市場調查,提供市場定義和概要,主要經營者與市場佔有率,市場的各種影響因素分析,價值鏈,市場機會·市場生命週期分析,癌區分·技術·治療區分·地區/各主要國家趨勢與市場規模的變化與預測,並彙整主要企業簡介等資訊。

第1章 市場概要

第2章 摘要整理

第3章 市場環境

  • 市場佔有率分析
  • 競爭經營者分析
    • 產品基準
    • 終端用戶的簡介
    • 前五名公司的財務分析

第4章 市場影響因素

  • 成長推進因素
  • 阻礙成長要素·課題
  • 產業的魅力

第5章 策略性市場分析

  • 價值鏈分析
  • 價格分析
  • 市場機會分析
  • 產品生命週期
  • 供應商·流通經銷商

第6章 市場分析·預測:各類型

  • 簡介
  • 肺癌
  • 血液癌
  • 骨癌
  • 腹部的癌
  • 眼癌
  • 口腔癌
  • 乳癌
  • 其他

第7章 市場分析·預測:各技術

  • 簡介
  • 影像
  • 生物標記
  • 內視鏡檢驗
  • 放射線
  • 其他

第8章 市場分析·預測:不同治療

  • 簡介
  • 外科手術
  • 放射線
  • 荷爾蒙療法
  • 化療
  • 基因治療
  • 其他

第9章 市場分析·預測:各階段

  • TNM分類
  • 階段0-4
  • 預後因素
  • 其他

第10章 市場分析·預測:男女

  • 男性
  • 女性

第11章 市場分析·預測:各地區

  • 簡介
  • 南北美洲
    • 美國
    • 加拿大
    • 墨西哥
    • 巴西
    • 其他
  • 歐洲
    • 英國
    • 德國
    • 西班牙
    • 法國
    • 義大利
    • 其他
  • 亞太地區
    • 中國
    • 韓國
    • 澳洲&紐西蘭
    • 日本
    • 印度
    • 其他
  • 其他地區
    • 中東·非洲

第12章 市場熵

  • 新產品的開發
  • 產品的投入·JV·M&A

第13章 企業簡介

  • Dias Orin S.P.A
  • Immunodiagnostic Systems Holdings Plc
  • Epigenomics Ag
  • Techlab, Inc.
  • Genextropy, Inc.
  • Lifecode
  • Genclis Sa
  • Target Discovery
  • Positive Bioscience
  • Celdara Medical, Llc
目錄

Cancer is a group of diseases, which involves the abnormal cell growth with the ability or the potential to spread to the other parts of the body. These cells form a neoplasm, where neoplasm or tumor is a group of cells that will undergo an unregulated growth. There are over 100 different known cancers that affect humans. The cancer screening or cancer testing, targets to detect the cancer before symptoms appear and also before it starts to spread throughout the body. Screening tests must be accurate and effectively appropriate in order to perform the necessary diagnosis. The most common sites of cancer among men are lung, prostate, colon, rectum, stomach and liver. The most common sites of cancer among women are breast, colon, rectum, lung, cervix and stomach.

The market for the cancer screening is found to be valued at $XX billion in 2015. At the end of 2015, the market is estimated to be $XX billion and is estimated to reach around $XX billion by 2021, growing at a CAGR of XX% from 2016 to 2021. This scenario is expected to further revolutionize the industry towards massive growth in the next 5 to 10 years because of the technological advancements and developments in the medicines in cancer diagnosis and effective health care.

Though the cost of diagnosis is one of the main constraints, government support and indigenous technologies from countries such China, India, and Japan is helping the market penetration. A simple blood test could be on the way to replacing the biopsy as the gold standard for detecting cancer, saving lives and money, according to researchers in the U.K. In their study, carried out on known or suspected primary or secondary lung cancer who were about to undergo surgery, the blood test was accurate in predicting the presence of cancer cells in nearly 70% of cases.

The above table explains the classification of cancer testing techniques which healthcare systems follow or usually doctors follow depending upon the type of cancer or techniques or by operation or selection of particular technique depending upon the stage of cancer. The stages of cancer refer to the severity of tumor or the time period from which it's been affecting the human body.

The major cause for the cancer is smoking and tobacco consumption and there are over 100 varieties of cancer depending upon various factors like the body part to which it is affected such as lung cancer, blood cancer, cervical cancer, breast cancer, abdominal cancer and screening techniques can be classified depending upon the type it is going to be diagnosed or may be depending upon the procedure which the particular method they follow such as imaging techniques (Computed tomography (CT) scan, Magnetic resonance imaging (MRI) scan, X-rays and other radiographic tests, Mammography, Ultrasound), endoscopy (arthroscopy, nronchoscopy, nystoscopy, laparoscopy, neuroendoscopy), bio marker tests, and also based on the technologies which the process follow and also on the treatment which they follow such as surgery, radiation, chemotherapy, immunotherapy, hormone therapy, gene therapy.

The high cancer rate is observed in countries such as Denmark, Australia, Belgium, Norway, Ireland, and North Korea whereas the low cancer rate is found in Niger, Columbia, Nepal, Namibia, and Bhutan etc. The most widely affected cancer areas where these cancer-testing techniques are followed can be segmented based on the geography such as Europe, America, APAC, and RoW can be segmented whereas the major portion is occupied by the Europe followed by Americas followed by APAC countries.

1. Market Overview

2. Executive Summary

3. Cacer Testing Market Landscape

  • 3.1. Market Share Analysis
  • 3.2. Comparative Analysis
    • 3.2.1. Product Benchmarking
    • 3.2.2. End User Profiling
    • 3.2.3. Top 5 Financials Analysis

4. Cancer Testing Market Forces

  • 4.1. Market Drivers
  • 4.2. Market Constraints & Challenges
  • 4.3. Attractiveness Of Cancer Testing Industry
    • 4.3.1. Power Of Suppliers
    • 4.3.2. Threats From New Entrants
    • 4.3.3. Power Of Buyer
    • 4.3.4. Threat From Substitute Product
    • 4.3.5. Degree Of Competition

5. Cancer Testing Market Strategic Analysis

  • 5.1. Cancer Testing - Value Chain Analysis
  • 5.2. Pricing Analysis
  • 5.3. Opportunity Analysis
  • 5.4. Product Life Cycle
  • 5.5. Suppliers And Distributors

6. Cancer Testing Market-By Type

  • 6.1. Introduction
  • 6.2. Lung Cancer
  • 6.3. Blood Cancer
  • 6.4. Bone Cancer
  • 6.5. Abdominal Cancer
  • 6.6. Eye Cancer
  • 6.7. Mouth Cancer
  • 6.8. Breast (Women) Cancer
  • 6.9. Others

7. Cancer Testing Market-By Technique

  • 7.1. Introduction
  • 7.2. Imaging Techniques
  • 7.3. Bio Marker Tests
  • 7.4. Endoscopy
  • 7.5. Radiation Techniques
  • 7.6. Others

8. Cancer Testing Market-By Treatment

  • 8.1. Introduction
  • 8.2. Surgery
  • 8.3. Radiation
  • 8.4. Hormone Therapy
  • 8.5. Chemo Therapy
  • 8.6. Gene Therapy
  • 8.7. Others

9. Cancer Testing Market-By Stage

  • 9.1. Tnm Stages
  • 9.2. Stages 0,1,2,3,4
  • 9.3. Prognostic Factors
  • 9.4. Other Staging Systems

10. Cancer Testing Market- By Gender

  • 10.1. Men
  • 10.2. Women

11. Cancer Testing Market-By Geography

  • 11.1. Americas
    • 11.1.1. U.S.
    • 11.1.2. Canada
    • 11.1.3. Mexico
    • 11.1.4. Brazil
    • 11.1.5. Rest Of America
  • 11.2. Europe
    • 11.2.1. U.K.
    • 11.2.2. Germany
    • 11.2.3. Spain
    • 11.2.4. France
    • 11.2.5. Italy
    • 11.2.6. Rest Of Europe
  • 11.3. Asia Pacific
    • 11.3.1. China
    • 11.3.2. South Korea
    • 11.3.3. Australia & New Zealand
    • 11.3.4. Japan
    • 11.3.5. India
    • 11.3.6. Rest Of Apac
  • 11.4. Rest Of The World (Row)
    • 11.4.1. Middle East Africa

12. Cancer Testing Market -Entropy

  • 12.1. New Product Developments
  • 12.2. Product Launchers, Jvs, Mergers And Acquisitions

13. Company Profiles

  • 13.1. Dias Orin S.P.A
  • 13.2. Immunodiagnostic Systems Holdings Plc
  • 13.3. Epigenomics Ag
  • 13.4. Techlab, Inc.
  • 13.5. Genextropy, Inc.
  • 13.6. Lifecode
  • 13.7. Genclis Sa
  • 13.8. Target Discovery
  • 13.9. Positive Bioscience
  • 13.10. Celdara Medical, Llc

More than 40 Companies are profiled in this Research Report, Complete List available on Request*

"*Financials would be provided on a best efforts basis for private companies"

Back to Top